title: Introduction: Institutional corruption and the pharmaceutical policy.
abstract: Today, the goals of pharmaceutical policy and medical practice are often undermined due to institutional corruption - that is, widespread or systemic practices, usually legal, that undermine an institution's objectives or integrity. In this symposium, 16 articles investigate the corruption of pharmaceutical policy, each taking a different look at the sources of corruption, how it occurs, and what is corrupted. We will see that the pharmaceutical industry's own purposes are often undermined. Furthermore, pharmaceutical industry funding of election campaigns and lobbying skews the legislative process that sets pharmaceutical policy. Moreover, certain practices have corrupted medical research, the production of medical knowledge, the practice of medicine, drug safety, the Food and Drug Administration's oversight of the pharmaceutical market, and the trustworthiness of patient advocacy organizations.
authors.affiliation: Professor at Suffolk University Law School and a Lab Fellow at the Edmond J. Safra Center for Ethics at Harvard University.
authors.forename: Marc A
authors.initials: MA
authors.lastname: Rodwin
mesh_terms: D035843:Biomedical Research; D016265:Conflict of Interest; D004345:Drug Industry; D040861:Ethics, Business; D006801:Humans; D010506:Periodicals as Topic; D011640:Public Policy; D015871:Scientific Misconduct